Literature DB >> 14760884

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

Scott M Hammer1, Roland Bassett, Kathleen E Squires, Margaret A Fischl, Lisa M Demeter, Judith S Currier, John W Mellors, Gene D Morse, Joseph J Eron, Jorge L Santana, Victor DeGruttola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14760884

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


× No keyword cloud information.
  8 in total

Review 1.  Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature.

Authors:  Albert M L Anderson; John A Bartlett
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

2.  Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.

Authors:  Susan Swindells; Hongyu Jiang; A Lisa Mukherjee; Mark Winters; Ronald J Bosch; David Katzenstein
Journal:  HIV Clin Trials       Date:  2011 Mar-Apr

3.  Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants.

Authors:  Parya Saberi; Torsten B Neilands; Eric Vittinghoff; Mallory O Johnson; Margaret Chesney; Susan E Cohn
Journal:  AIDS Patient Care STDS       Date:  2015-01-23       Impact factor: 5.078

4.  Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.

Authors:  Gene D Morse; Susan Rosenkranz; Michael F Para; Yoninah Segal; Robin Difrancesco; Elizabeth Adams; Barbara Brizz; Kevin E Yarasheski; Richard C Reichman
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 5.  Nelfinavir: a review of its use in the management of HIV infection.

Authors:  Caroline M Perry; James E Frampton; Paul L McCormack; M Asif A Siddiqui; Risto S Cvetković
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

Authors:  Lisa M Demeter; Victor DeGruttola; Stephanie Lustgarten; Daniel Bettendorf; Margaret Fischl; Susan Eshleman; William Spreen; Bach-Yen Nguyen; Christine E Koval; Joseph J Eron; Scott Hammer; Kathleen Squires
Journal:  HIV Clin Trials       Date:  2008 Jan-Feb

7.  A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.

Authors:  Lisa M Demeter; Hongyu Jiang; A Lisa Mukherjee; Gene D Morse; Robin DiFrancesco; Robert DiCenzo; Carrie Dykes; Prakash Sista; Lee Bacheler; Karin Klingman; Alex Rinehart; Mary Albrecht
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

8.  Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

Authors:  Ashish Chandwani; Jonathan Shuter
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.